GooderhamMJ.Van VoorheesAS.LebwohlMG. An update on generalized pustular psoriasis. Expert Rev Clin Immunol. 2019;15(9):907-919.doi:10.1080/1744666X.2019.1648209
2.
FurueK.YamamuraK.TsujiGet al. Highlighting interleukin-36 signalling in plaque psoriasis and pustular psoriasis. Acta Derm Venereol. 2018;98(1):5-13.doi:10.2340/00015555-2808
3.
BaumP.VisvanathanS.BossertS. Treatment with spesolimab, an anti-interleukin-36 receptor antibody, in patients with generalized pustular psoriasis, is associated with the downregulation of biomarkers linked to innate, Th1/Th17 and neutrophilic pathways. ESDR meeting September 21; 2019; Bordeaux, France.
4.
BachelezH.ChoonS-E.MarrakchiSet al. Inhibition of the Interleukin-36 pathway for the treatment of generalized pustular psoriasis. N Engl J Med. 2019;380(10):981-983.doi:10.1056/NEJMc1811317
5.
KhanskayaI.PinkstaffJ.MarinoMH. A phase 1 study of ANB019, an anti-IL-36 receptor monoclonal antibody, in healthy volunteers. EAACI Congress May 26–30; 2018; Munich, Germany.
